Skip to main content

Table 1 Summary of the EORTC and PERCIMT response criteria

From: Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study

  EORTC PERCIMT
CMR Complete resolution of 18F-FDG uptake within the tumor volume Complete resolution of all pre-existing18F-FDG avid lesions. No new, 18F-FDG avid lesions
PMR Decrease in tumor SUV > 25% after more than 1 therapeutic cycle Complete resolution of some pre-existing18F-FDG avid lesions. No new, 18F-FDG avid lesions
SMD Increase in tumor SUV < 25% or decrease in SUV < 15% Neither PMD nor PMR/CMR
PMD Increase in tumor SUV > 25% or appearance of new lesions  ≥ 4 new lesions of less than 1.0 cm in functional diameter or
 ≥ 3 new lesions between 1.0 and 1.5 cm in functional diameter or
 ≥ 2 new lesions of more than 1.5 cm in functional diameter
  1. EORTC, European Organization for Research and Treatment of Cancer; PERCIMT, PET Response Evaluation Criteria for Immunotherapy; CMR, complete metabolic response; PMR, partial metabolic response; SMD, stable metabolic disease; PMD, progressive metabolic disease; SUV, standardized uptake value